vs
Apellis Pharmaceuticals, Inc.（APLS）与BLACKBAUD INC（BLKB）财务数据对比。点击上方公司名可切换其他公司
BLACKBAUD INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.4倍（$281.1M vs $199.9M），BLACKBAUD INC净利率更高（11.1% vs -29.5%，领先40.6%），BLACKBAUD INC同比增速更快（4.2% vs -5.9%），BLACKBAUD INC自由现金流更多（$37.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -1.1%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Blackbaud是全球知名的云服务提供商，专注为非营利组织、基金会、企业、教育机构、医疗机构、宗教团体及个人公益推动者提供技术支持，旗下产品覆盖筹款、网站管理、客户关系管理、数据分析、财务管理、票务系统、教育管理等多元场景。
APLS vs BLKB — 直观对比
营收规模更大
BLKB
是对方的1.4倍
$199.9M
营收增速更快
BLKB
高出10.1%
-5.9%
净利率更高
BLKB
高出40.6%
-29.5%
自由现金流更多
BLKB
多$51.3M
$-14.3M
两年增速更快
APLS
近两年复合增速
-1.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $281.1M |
| 净利润 | $-59.0M | $31.1M |
| 毛利率 | — | 59.2% |
| 营业利润率 | -25.6% | 18.3% |
| 净利率 | -29.5% | 11.1% |
| 营收同比 | -5.9% | 4.2% |
| 净利润同比 | -62.2% | 620.3% |
| 每股收益（稀释后） | $-0.40 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSBLKB
| Q1 26 | — | $281.1M | ||
| Q4 25 | $199.9M | $295.3M | ||
| Q3 25 | $458.6M | $281.1M | ||
| Q2 25 | $178.5M | $282.0M | ||
| Q1 25 | $166.8M | $269.9M | ||
| Q4 24 | $212.5M | $302.1M | ||
| Q3 24 | $196.8M | $286.6M | ||
| Q2 24 | $199.7M | $287.3M |
净利润APLSBLKB
| Q1 26 | — | $31.1M | ||
| Q4 25 | $-59.0M | $36.7M | ||
| Q3 25 | $215.7M | $47.5M | ||
| Q2 25 | $-42.2M | $26.5M | ||
| Q1 25 | $-92.2M | $4.3M | ||
| Q4 24 | $-36.4M | $-346.4M | ||
| Q3 24 | $-57.4M | $18.3M | ||
| Q2 24 | $-37.7M | $21.2M |
毛利率APLSBLKB
| Q1 26 | — | 59.2% | ||
| Q4 25 | — | 58.3% | ||
| Q3 25 | — | 59.6% | ||
| Q2 25 | — | 59.7% | ||
| Q1 25 | — | 57.5% | ||
| Q4 24 | — | 53.8% | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 56.0% |
营业利润率APLSBLKB
| Q1 26 | — | 18.3% | ||
| Q4 25 | -25.6% | 20.0% | ||
| Q3 25 | 48.7% | 19.4% | ||
| Q2 25 | -18.6% | 20.3% | ||
| Q1 25 | -50.0% | 7.3% | ||
| Q4 24 | -12.3% | -121.5% | ||
| Q3 24 | -24.0% | 14.4% | ||
| Q2 24 | -14.7% | 14.4% |
净利率APLSBLKB
| Q1 26 | — | 11.1% | ||
| Q4 25 | -29.5% | 12.4% | ||
| Q3 25 | 47.0% | 16.9% | ||
| Q2 25 | -23.6% | 9.4% | ||
| Q1 25 | -55.3% | 1.6% | ||
| Q4 24 | -17.1% | -114.6% | ||
| Q3 24 | -29.2% | 6.4% | ||
| Q2 24 | -18.9% | 7.4% |
每股收益（稀释后）APLSBLKB
| Q1 26 | — | $0.67 | ||
| Q4 25 | $-0.40 | $0.75 | ||
| Q3 25 | $1.67 | $0.98 | ||
| Q2 25 | $-0.33 | $0.55 | ||
| Q1 25 | $-0.74 | $0.09 | ||
| Q4 24 | $-0.30 | $-6.82 | ||
| Q3 24 | $-0.46 | $0.35 | ||
| Q2 24 | $-0.30 | $0.41 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $34.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $34.6M |
| 总资产 | $1.1B | $2.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSBLKB
| Q1 26 | — | $34.1M | ||
| Q4 25 | $466.2M | $38.9M | ||
| Q3 25 | $479.2M | $38.3M | ||
| Q2 25 | $370.0M | $41.6M | ||
| Q1 25 | $358.4M | $37.2M | ||
| Q4 24 | $411.3M | $67.6M | ||
| Q3 24 | $396.9M | $34.6M | ||
| Q2 24 | $360.1M | $30.4M |
总债务APLSBLKB
| Q1 26 | — | — | ||
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.0B |
股东权益APLSBLKB
| Q1 26 | — | $34.6M | ||
| Q4 25 | $370.1M | $85.1M | ||
| Q3 25 | $401.2M | $108.2M | ||
| Q2 25 | $156.3M | $72.7M | ||
| Q1 25 | $164.2M | $17.5M | ||
| Q4 24 | $228.5M | $126.8M | ||
| Q3 24 | $237.1M | $544.8M | ||
| Q2 24 | $264.3M | $577.5M |
总资产APLSBLKB
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.1B | $2.4B | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $821.4M | $2.6B | ||
| Q1 25 | $807.3M | $2.1B | ||
| Q4 24 | $885.1M | $2.5B | ||
| Q3 24 | $901.9M | $2.6B | ||
| Q2 24 | $904.5M | $3.0B |
负债/权益比APLSBLKB
| Q1 26 | — | — | ||
| Q4 25 | — | 13.06× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 8.50× | ||
| Q3 24 | — | 1.84× | ||
| Q2 24 | — | 1.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $51.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $37.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 13.2% |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 1.65× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $294.1M |
8季度趋势，按日历期对齐
经营现金流APLSBLKB
| Q1 26 | — | $51.5M | ||
| Q4 25 | $-14.2M | $58.0M | ||
| Q3 25 | $108.5M | $139.2M | ||
| Q2 25 | $4.4M | $66.9M | ||
| Q1 25 | $-53.4M | $1.4M | ||
| Q4 24 | $19.4M | $73.6M | ||
| Q3 24 | $34.1M | $104.0M | ||
| Q2 24 | $-8.3M | $53.1M |
自由现金流APLSBLKB
| Q1 26 | — | $37.0M | ||
| Q4 25 | $-14.3M | $55.0M | ||
| Q3 25 | $108.3M | $135.7M | ||
| Q2 25 | $4.4M | $66.3M | ||
| Q1 25 | $-53.4M | $712.0K | ||
| Q4 24 | $19.3M | $73.4M | ||
| Q3 24 | — | $102.9M | ||
| Q2 24 | $-8.4M | $48.0M |
自由现金流率APLSBLKB
| Q1 26 | — | 13.2% | ||
| Q4 25 | -7.1% | 18.6% | ||
| Q3 25 | 23.6% | 48.3% | ||
| Q2 25 | 2.5% | 23.5% | ||
| Q1 25 | -32.0% | 0.3% | ||
| Q4 24 | 9.1% | 24.3% | ||
| Q3 24 | — | 35.9% | ||
| Q2 24 | -4.2% | 16.7% |
资本支出强度APLSBLKB
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.0% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.0% | 0.4% | ||
| Q2 24 | 0.0% | 1.8% |
现金转化率APLSBLKB
| Q1 26 | — | 1.65× | ||
| Q4 25 | — | 1.58× | ||
| Q3 25 | 0.50× | 2.93× | ||
| Q2 25 | — | 2.53× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 5.69× | ||
| Q2 24 | — | 2.50× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
BLKB
暂无分部数据
